Form D · Biotechnology
Avalo Therapeutics, Inc.
Rockville, MD · CIK 0001534120
Offering snapshot reported Apr 9, 2024 · SEC filing
- Reported sold
- $131M Offering amount: $200M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 27, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 9, 2024 | Initial | $130,601,986 | No comparison | 25 | SEC filing |
| May 8, 2017 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Sep 16, 2016 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Jul 21, 2014 | Initial | $16,259,016 | No comparison | 13 | SEC filing |
| Sep 6, 2013 | Initial | $6,805,883 | No comparison | 146 | SEC filing |
| Apr 4, 2012 | Initial | $22,137,301 | No comparison | 156 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $6.94M
- Form D file number
- 021-510110
The Total Remaining to be Sold represents warrants issued at closing that have not yet been exercised.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Oppenheimer & Co. Inc. | 249 |
Source: Form D, filed Apr 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas Aasen | Director |
| June Almenoff, M.D., Ph.D. | Director |
| Sol J. Barer | Director |
| Eugene A. Bauer | Director |
| Isaac Blech | Director |
| John Catsimatidis | Director |
| Mitchell Chan | Director |
| Bernadine Heather Fraser | Executive |
| Jonathan Goldman, M.D. | Director |
| Phil Gutry | Director |
| Uli Hacksell | Director, Executive |
| John Kaiser | Executive |
| Aaron Kantoff | Director |
| Gilla Kaplan, Ph.D. | Director |
| Karen Krumeich | Executive |
| Ronald Marcus | Executive |
| Reza Mazhari | Executive |
| Mariam E Morris | Executive |
| Garry Neil, M.D. | Director, Executive |
| Federica F. O'brien | Executive |
| Blake M. Paterson | Director, Executive |
| Magnus Persson | Director |
| Magnus Persson, M.D., Ph.D. | Director |
| Sharon Rowland | Executive |
| Behshad Sheldon | Director |
| Cary Sucoff | Director |
| Cary W. Sucoff, Jr. | Director |
| Mayukh Sukhatme | Director |
| Christopher Sullivan | Executive |
| Frank Torti | Director |
| Samantha Truex | Director |
| James Vornov | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
540 Gaither Road Suite 400
Rockville, MD, 20850
Rockville, MD, 20850